Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from RemeGen Co. Ltd. Class H ( (HK:9995) ) is now available.
RemeGen Co., Ltd. announced that its drug Telitacicept met the primary endpoint in a Phase III clinical trial for primary Sjögren’s syndrome in China. This marks a significant milestone as Telitacicept is the first BLyS/APRIL dual-target fusion protein drug to complete such a study in this field. The trial demonstrated the drug’s efficacy and safety, addressing a significant unmet clinical need in Sjögren’s syndrome treatment. The company plans to submit a Biologics License Application to the National Medical Products Administration of China and present the data at international conferences. Telitacicept has also been recommended by multiple guidelines in China and has received fast track designation from the U.S. FDA for its Sjögren’s syndrome indication.
The most recent analyst rating on (HK:9995) stock is a Buy with a HK$19.59 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the pharmaceutical industry. The company focuses on developing innovative biologic drugs, with a particular emphasis on autoimmune diseases and cancer therapies.
Average Trading Volume: 11,660,673
Technical Sentiment Signal: Buy
Current Market Cap: HK$38.89B
See more insights into 9995 stock on TipRanks’ Stock Analysis page.